FOX04-DRI

FOX04-DRI

FOX04-DRI

ʻO FOXO4-DRI kahi pūhui senolyt i ʻike ʻia ʻo IT-Inhibitor peptide e hōʻike ana i nā waiwai anti-aging..

Pane wikiwiki

We supply high-purity FOX04-DRI peptide with stable D-retro-inverso structure and excellent protease resistance. This targeted anti-aging raw material ensures precise senescent cell clearance, supporting global wholesale supply and customized biotech laboratory experimental projects.

SKU: 198835 Māhele:
Kaʻana like i kāu aloha

ʻO ka noiʻi nui ʻana i nā mīkini senescence cellular i alakaʻi i ka hoʻomohala ʻana o FOXO4-DRI, he pūhui senolytic i kapa ʻia ʻo IT-Inhibitor peptide. Hōʻike kēia peptide bioactive i nā waiwai anti-kahiko.

I loko o nā pūnaewele kahiko, ʻo kahi laʻana, Hoʻopili ʻo FOXO4 i p53, ka hana ʻana i kahi paʻakikī i kapa ʻia ʻo FOXO4-p53 aggregates. Ke hana nei kēia paʻakikī ma ke ʻano he mea pale o apoptosis hoʻomaka. No laila, hooloihi keia launa ana i ke ola o cellular senescence a alakaʻi i ko lākou hōʻiliʻili ʻana i ka manawa.

ʻIke ʻia, ʻAʻole kuhikuhi pono ʻo FOXO4-DRI iā FOXO1, FOXO3, aiʻole nā ​​protein p53. aka, pili pono ia me ka pūnaewele paʻa o FOXO4 i loko o ka paʻakikī FOXO4-p53. Hoʻoikaika kēia pilina i ka dissociation o ka paʻakikī, hoopuka p53, a ma laila e hoʻāla hou ai i ka apoptosis i hoʻokomo ʻia i ka p53, ʻoiai e mālama ana i nā cell maʻamau mai nā hopena ʻaoʻao.

Hōʻike kekahi mau hōʻike i ka ikaika o ka FOXO4-DRI i ka pepehi ʻana i nā cell senescent.. Eia kekahi, Hōʻike nā haʻawina e hoʻohuli ʻo FOXO4-DRI i ka emi ʻana o ke kino pili makahiki: hoʻonui ia i ka hoʻomanawanui kino a me ka hana kaʻa, hoʻihoʻi i ka hana renal a me ka ulu lauoho, a pēlā e hoʻolohi ai i ka pohō o ka ʻiʻo pili makahiki. ʻo kahi laʻana, Hōʻike maopopo nā kiʻi ʻiole kahiko i kēia mau pōmaikaʻi. Eia hou, FOXO4-DRI hoemi ʻaʻa mau a me ka pōʻino o ke kino i ka microenvironment post-chemotherapy, no laila e hoʻomaikaʻi ai i ka maikaʻi o ke ola a me ka hāpai ʻana i ke olakino lōʻihi i nā maʻi maʻi maʻi.

Kaʻina

H-D-Leu-D-Thr-D-Leu-D-Arg-D-Lys-D-Glu-D-Pro-D-Ala-D-Ser-D-Glu-D-Ile-D- Ala-D-Gln-D-Ser-D-Ile-D-Leu-D-Glu-D-Ala-D-Tyr-D-Ser-D-Gln-D-Asn-D-Gly- D-Trp-D-Ala-D-Asn-D-Arg-D-Arg-D-Ser-D-Gly-D-Gly-D-Lys-D-Arg-D-Pro-D-Pr o-D-Pro-D-Arg-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Lys-D-Lys-D-Arg-D-Gly-OH

Helu CAS

2460055-10-9

ʻĀpana Molekala

C228H388N86O64

Kaumaha Molekala

5358.05

Noiʻi No Foxo4-dri Pono

1.Hookomo koho o Senescent Cell Apoptosis

ʻO ka hana mua o FOXO4-DRI e pili ana i ka hoʻoulu ʻia ʻana o ka make cell programmed i nā cell senescent.. Eia, Ke hana nei ka p53 ma ke ʻano he trans-activating factor no nā genes pro-apoptotic, ka hoʻoulu ʻana i ka apoptosis. Eia naʻe, ma lalo o nā kūlana physiological maʻamau, ka FOXO4-p53 complex e hoʻopio i kēia hana apoptotic.

Ma ka hoʻokūkū ʻana no ka paʻa p53, Hoʻopilikia ka FOXO4-DRI i ka pilina FOXO4-p53. Hoʻomaka kēia pilikia i ke ala apoptosis intrinsic i nā cell senescent.

I nā ʻiole kahiko, ʻO ka mālama ʻana me FOXO4-DRI i alakaʻi i ka ulu hou ʻana o ka lauoho e like me nā ʻiole waena a me ka hoʻomaikaʻi nui ʻana i ka hana kaʻa..

2.Ka maikaʻi o ke ola no nā maʻi maʻi maʻi maʻi

Ke ʻimi nei nā mea noiʻi iā FOXO4-DRI ma ke ʻano he lāʻau adjuvant hiki ke hoʻomaikaʻi i ka maikaʻi o ke ola no nā poʻe maʻi maʻi maʻi ma hope ka lāʻau lapaʻau. ʻOiai e pili ana ka nui o nā mea anticancer nā pūnaeʻa tumora, hana pū lākou i ka hōʻeha kikoʻī ʻole i nā cell maʻamau, hoʻonui i ke kaumaha o ka senescence i hoʻokomo ʻia i ka therapy(TIS).

Hōʻoia nā haʻawina nui e hiki i ka FOXO4-DRI ke hoʻopau pono i nā cell senescent kuʻuna a me ka mālama ʻana., hoʻomaikaʻi i ka chemotherapy-induced maʻi palupalu. ʻo kahi laʻana, Ua hōʻike ʻia kahi haʻawina ma Cell i ka hoʻomaikaʻi ʻana a me ke ola ʻana i nā ʻiole i mālama ʻia i ka chemotherapy. Ke hōʻike nei kēia mau ʻike i ka hiki ke hoʻoikaika kino adjuvant o FOXO4-DRI i ka oncology.

3.ʻO ka hoʻomaikaʻi ʻana i ka maʻi maʻi ate

In NASH(ʻO ka steatohepatitis no ka waiʻona) nā maʻi, ʻulaʻula hōʻiliʻili i loko o ke ake a huna i nā molekala pro-inflammatory a me pro-fibrotic ma o ka phenotype huna e pili ana i ka senescence (SASP), hoʻokele maʻi holomua. Ua ʻike ʻia nā haʻawina e hoʻohana ana i ka ʻiole NASH model ua hoʻopau ʻo FOXO4-DRI i kēia mau pūnaewele hepatic senescent, ke kāohi nei i ka hana SASP ma kona kumu.

4.Lapaʻau ʻana i nā ʻiole me ka Bleomycin-Induced Pulmonary Fibrosis

Hoʻomaka ka FOXO4-DRI i ka wehe ʻana i ka nuklea p53 a me ka wehe ʻana o ka paʻakikī FOXO4-p53. I nā ʻiole i hoʻokomo ʻia i ka bleomycin, lapaʻau me FOXO4-DRI emi pae o Collagen, ʻano I, alpha 1 (Kol1a1) a me ka α-SMA ma nā ʻiʻo māmā. Hōʻike kēia hōʻemi i ka emi ʻana o ka hana ʻana o ka matrix extracellular a me ka pale ʻana o myofibroblast hoʻoulu ʻana.

ʻOiai ʻaʻole i wehewehe piha ka haʻawina i ke ala pololei o ka launa pū ʻana o FOXO4-DRI me p53., ua hōʻike maikaʻi ʻia ka pale ʻana i ka fibrosis, e hōʻike ana i kahi hoʻolālā therapeutic kūpono no idiopathic pulmonary fibrosis (IPF).

5.Hoʻohaʻahaʻa i ka makahiki Hypogonadism (ʻAʻohe Testosterone)

ʻO ka hypogonadism hoʻomaka mua o ke kāne he maʻi maʻi e pili ana i ka ʻelemakule e hōʻino ana i nā pūnaewele Leydig kahiko. Hiki ke hoʻomaʻemaʻe i ka hana o ka ʻiʻo i ka hoʻomaʻemaʻe ʻana i kēia mau senescent cell. Hōʻike nā haʻawina e hana pono ana ʻo FOXO4-DRI i ka testicular kanaka Leydig cell. ʻO ka lawelawe ʻana i nā ʻiole kahiko i hoʻomaikaʻi i ka microenvironment testicular, pale ana i ka nele o ka testosterone pili makahiki. A 2021 Ua hōʻike ka haʻawina i ka piʻi nui ʻana o nā pae testosterone serum i nā ʻiole kahiko i mālama ʻia.

ʻO ka hana i manaʻo ʻia e pili ana i ka hoʻopau ʻana i ka localization nuklea p53 a me ka dissociation o ka paʻakikī FOXO4-p53., ka hopena i ka apoptosis cell senescent. Hōʻike kēia mau hopena i kahi ala lapaʻau kūpono no ka mālama ʻana i ka hōʻemi testosterone pili makahiki.

COA

HPLC

MS

(1) Kong, Y.-X.; Li, Z.-S.; Liu, Y.-B.; Pan, B.; Fu, X.; Xiao, R.; ʻO Yan, L. Hoʻokomo ʻo FOXO4-DRI i ke keloid senescent fibroblast apoptosis ma o ka hoʻolaha ʻana i ka hoʻoneʻe nuklea o ka upregulated p53-serine. 15 phosphorylation. Kūkākūkā Biology 2025, 8 (1). DOI: 10.1038/s42003-025-07738-0.

(2) ʻO Baʻa, M. P.; Brandt, R. M. C.; Ua noʻonoʻo ʻo ia, ʻO D. A.; Klein, J. ʻO D. D.; Derks, K. Ua ʻōlelo ʻo W. J.; Bourgeois, B. R. M.; Stryeck, S.; Rijksen, Y.; mai Willigenburg, H.; Feijtel, ʻO D. A.; et al. Hoʻihoʻi hou ka Apoptosis o nā Senescent Cells i ka Tissue Homeostasis i pane i ka Chemotoxicity a me ka ʻelemakule.. Kelepona 2017, 169 (1), 132-147.e116. DOI: 10.1016/j.cell.2017.02.031.

(3) ʻO Tayyar, A.; Ikaika, ʻO G.; O'Neill, Ua ʻōlelo ʻo T. Ua ʻōlelo ʻo W.; Lee, ʻO D. M.; ʻO Salman, A. J.; Finn, J. D.; Bartfai, ʻO G. r.; ʻO Boonen, S.; ʻO Casanueva, F. F.; Giwercman, A.; et al. Nā ʻano o ke kula kiʻekiʻe, Papahana, a me ka Hypogonadism i uku ʻia i nā kāne ʻelemakule: ʻO nā hōʻike mai ka European Male Aging Study. ʻO ka Journal of Clinical Endocrinology & ʻO ka metabolism 2010, 95 (4), 1810-1818. DOI: 10.1210/jc.2009-1796.

(4) Liu, Y.; Hou, Q.; ʻO Wang, R.; Liu, Y.; ʻO Cheng, Z. Hoʻokumu ʻo FOXO4-D-Retro-Inverso i ka hana ʻana o ka matrix extracellular i nā fibroblasts a hoʻomaikaʻi i ka bleomycin-induced pulmonary fibrosis i nā ʻiole. Naunyn-Schmiedeberg's Archives of Pharmacology 2023, 396 (10), 2393-2403. DOI: 10.1007/s00210-023-02452-2.

(5) ʻO Zhang, C.; Xie, Y.; ʻO Chen, H.; Lv, L.; ʻO Yao, J.; ʻO Zhang, M.; Xia, K.; Feng, X.; Li, Y.; Liang, X.; et al. Hoʻopau ʻo FOXO4-DRI i ka lawa ʻole o ka huna ʻana o ka testosterone e pili ana i ka makahiki ma o ka huli ʻana i nā cell Leydig senescent i nā ʻiole kahiko.. ʻelemakule 2020, 12 (2), 1272-1284. DOI: 10.18632/elemakule.102682.

kikoʻī

10 mg, 5 mg

Kaʻina:

H-D-Leu-D-Thr-D-Leu-D-Arg-D-Lys-D-Glu-D-Pro-D-Ala-D-Ser-D-Glu-D-Ile-D- Ala-D-Gln-D-Ser-D-Ile-D-Leu-D-Glu-D-Ala-D-Tyr-D-Ser-D-Gln-D-Asn-D-Gly- D-Trp-D-Ala-D-Asn-D-Arg-D-Arg-D-Ser-D-Gly-D-Gly-D-Lys-D-Arg-D-Pro-D-Pr o-D-Pro-D-Arg-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Lys-D-Lys-D-Arg-D-Gly-OH

CAS:

2460055-10-9

M.W:

5358.15 g/mol

Home Huli Whatsapp Nā lawelawe Huahana